AzTrials
AzTrials

Noonan SyndromeNOORHANCT06550635

Joint and Hematologic Disorders of Noonan Syndrome: French Descriptive Cross-sectional Study

An observational study of Noonan Syndrome, run by University Hospital, Brest at 4 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Noonan's syndrome is a rare genetic disease, estimated to be between 1: 1000 to 1: 2500 and characterized by cardiothoracic malformations, sometimes mental retardation, but also by hematologic abnormalities and joint involvement. These are poorly described in the literature. Read more about this study

Who is it for?
Ages 0 to 20 years
Conditions the study is for
Noonan Syndrome
How many people
71 participants
Where
4 sitesFrance
Study dates
2 Jul 2019to 28 Mar 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 20 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: French pediatric population, followed for a syndrome of Noonan clinically confirmed by the criteria of Van der Burgt.

Who may be able to join

  • Patients ≤ 20 years at the time of diagnosis
  • Noonan syndrome confirmed by van der Burgt score
  • At least one consultation in the participating center

Who cannot join

  • Patient > 20 years old at the time of diagnosis
  • Absence of diagnostic criteria for van der Burgt's Noonan syndrome
  • Other rasopathies
  • Genetic mutations of MEK1, MEK2 and HRAS (which are associated with cardi-faci-cutaneous syndrome and Costello syndrome)
  • Refusal of participation in the study

Trial locations and contacts

4 sites in 1 country.

France4 sites
  • CHRU de Brest

    Brest, 29609

  • CHU de Caen

    Caen, 14033

  • CHU de Nantes

    Nantes, 44093

  • CHU de Toulouse

    Toulouse, 31000

Other trials in France

About this study

Official title: Joint and Hematologic Disorders of Noonan Syndrome: French Descriptive Cross-sectional Study (NOORHA)

Noonan's syndrome is a rare genetic disease, estimated to be between 1: 1000 to 1: 2500 and characterized by cardiothoracic malformations, sometimes mental retardation, but also by hematologic abnormalities and joint involvement. These are poorly described in the literature. The aim of this work is therefore to describe the frequency and type of these manifestations in the French pediatric population and to compare patients with and without these disorders.

Read the detailed description

Noonan Syndrome is a genetic disease whose prevalence is not clearly defined and would be between 1/1000 and 1/2500.

Affected patients have various morphological abnormalities, cardiothoracic malformations, sometimes mental retardation, but also haematological abnormalities and joint damage.

Diagnostic criteria have been proposed among which, the most used are van der Burgt's criteria.

Genetics is heterogeneous. A genetic abnormality can be found in 75% of cases. Affected genes encode proteins involved in the RAS / MAPK pathway (Mitogen Activated Protein Kinase), resulting in deregulation of this pathway. The latter is involved in several development processes determining morphotype, organogenesis, synaptic plasticity and growth.

There are also thoracic and abdominal deformities (upper pectus carinatum and inferior excavatum, large nipple spacing), spinal deformities in 30% of cases with a recommended correction in 2/3 of the cases. It is described ulna valgus and genuvalgum.

Concerning haematological disorders:

Children with Noonan Syndrome are predisposed to a number of hematologic abnormalities. The most common haematological lesions are coagulopathies caused by a deficiency of coagulation factors or platelet dysfunction that seem to affect one third of patients.

Concerning rheumatological disorders:

Hemophilias, due to recurrent bleeding, may develop secondarily hemophilic arthropathies.

There are several pediatric cases of granulomatous gigantocellular tumors and pigmented villonodular synovitis that are synovial proliferations affecting the joints, tendon sheaths and bursae. Villonodular synovitis is also a granulomatous giant cell lesion. Unlike villonodular synovitis in the general population, reported cases are frequently polyarticular. The diffuse villonodular synovitis in the general population has an estimated frequency of 1.8 cases per million. It is most often developed in adulthood (20-50 years), but can also begin in childhood.

There has been no description of arthritis or isolated arthralgia.

Regarding abnormalities of bone metabolism, even if there is a tendency to short stature, and there are bone dysplasias, little information is available regarding the mineralization and bone metabolism in Noonan syndrome. An increase in bone resorption has been observed in the RAS-MAPK pathway and low bone mineral density has already been described in this population.

Joint lesions and their evolution remain poorly described in the literature. The early pediatric diagnosis of Noonan's syndrome is important in detecting multiple organ damage. Early management should improve joint functional prognosis.

The objective of this work is therefore to evaluate the frequency and type of these events in the French pediatric population and to compare patients with and without these disorders, and to observe the proposed treatments.

Conditions
Noonan Syndrome
Medical subject headings
Noonan Syndrome

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Description of joint and hematologic disorders in patients with Noonan syndrome clinically confirmed by Van der Burgt criteria.

    Joint disorders

    Measured: Inclusion (Day 0)

  2. Description of joint and hematologic disorders in patients with Noonan syndrome clinically confirmed by Van der Burgt criteria.

    hematologic disorders

    Measured: Inclusion (Day 0)

Secondary outcomes (2)
  1. Comparison of patients with and without joint involvement.

    Comparison of patients with and without joint involvement.

    Measured: Inclusion (Day 0), Each year

  2. Comparison of patients with and without joint involvement.

    Evolution of joint damage with and without treatment.

    Measured: Inclusion (Day 0), Each year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2024
  2. Study start2 Jul 2019
  3. Primary completion28 Mar 2020
  4. Study completion28 Mar 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
71 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06550635
Sponsor's protocol ID
NOORHA (29BRC19.0038)
Acronym
NOORHA
Status last verified
Jun 2020
First submitted
5 Jun 2019
Last updated
13 Aug 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Noonan Syndrome, run by University Hospital, Brest at 4 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Description of joint and hematologic disorders in patients with Noonan syndrome clinically confirmed by Van der Burgt criteria. (time frame: Inclusion (Day 0)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in